Index -
P/E 64.64
EPS (ttm) 0.12
Insider Own 0.00%
Shs Outstand 1.51B
Perf Week -6.66%
Market Cap 12.08B
Forward P/E 8.58
EPS next Y 0.93
Insider Trans -
Shs Float 1.51B
Perf Month -5.22%
Income 182.16M
PEG 4.75
EPS next Q 0.12
Inst Own 28.97%
Short Float 0.38%
Perf Quarter 7.10%
Sales 17.42B
P/S 0.69
EPS this Y 6662.33%
Inst Trans -1.60%
Short Ratio 0.81
Perf Half Y 31.20%
Book/sh 6.92
P/B 1.16
EPS next Y 37.70%
ROA 0.64%
Short Interest 5.75M
Perf Year 35.42%
Cash/sh 0.41
P/C 19.36
EPS next 5Y 13.60%
ROE 1.69%
52W Range 5.67 - 9.27
Perf YTD 3.10%
Dividend Est. 0.05 (0.60%)
P/FCF 11.15
EPS past 5Y -17.84%
ROI 0.96%
52W High -13.76%
Beta 1.49
Dividend TTM -
Quick Ratio 0.47
Sales past 5Y 5.36%
Gross Margin 32.41%
52W Low 40.92%
ATR (14) 0.24
Dividend Ex-Date Dec 13, 2019
Current Ratio 0.74
EPS Y/Y TTM -67.25%
Oper. Margin 12.14%
RSI (14) 35.39
Volatility 3.64% 2.76%
Employees 46063
Debt/Eq 0.80
Sales Y/Y TTM 11.11%
Profit Margin 1.05%
Recom 1.31
Target Price 10.92
Option/Short Yes / Yes
LT Debt/Eq 0.71
EPS Q/Q -166.96%
Payout 0.00%
Rel Volume 0.86
Prev Close 8.08
Sales Surprise 0.15%
EPS Surprise -123.47%
Sales Q/Q 9.69%
Earnings Apr 25 BMO
Avg Volume 7.11M
Price 7.99
SMA20 -8.02%
SMA50 -3.28%
SMA200 6.62%
Trades
Volume 6,100,475
Change -1.11%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-09-24 Downgrade
Barclays
Overweight → Equal Weight
$9
Jan-09-24 Upgrade
BofA Securities
Neutral → Buy
$9
Nov-02-23 Resumed
Citigroup
Buy
$8.20
May-15-23 Downgrade
BofA Securities
Buy → Neutral
$6.80 → $7.20
May-05-23 Downgrade
Citigroup
Buy → Neutral
May-04-23 Upgrade
Goldman
Neutral → Buy
$5.90 → $9
Dec-08-22 Initiated
Redburn
Neutral
$4.90
Sep-20-22 Downgrade
Exane BNP Paribas
Outperform → Neutral
$4
Jun-10-22 Downgrade
Berenberg
Buy → Hold
Apr-20-22 Upgrade
Credit Suisse
Neutral → Outperform
$6.70
Apr-05-22 Downgrade
Goldman
Buy → Neutral
$9.20 → $6
Feb-23-22 Downgrade
Credit Suisse
Outperform → Neutral
$6.40
Oct-11-21 Upgrade
Citigroup
Neutral → Buy
$9.80 → $9.30
Jun-15-21 Resumed
Berenberg
Buy
$10
Apr-23-21 Upgrade
Exane BNP Paribas
Neutral → Outperform
$9.50
Jan-28-21 Downgrade
Exane BNP Paribas
Outperform → Neutral
$6.50
Jan-20-21 Downgrade
Citigroup
Buy → Neutral
Sep-29-20 Initiated
UBS
Buy
Sep-15-20 Upgrade
Goldman
Neutral → Buy
$5.10
Sep-11-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$6
Show Previous Ratings
Mar-13-24 07:03PM
Mar-09-24 12:45PM
Dec-05-23 05:20PM
Dec-04-23 08:14AM
Oct-27-23 10:39AM
08:30AM
Loading…
Oct-24-23 08:30AM
Oct-16-23 08:00AM
Sep-06-23 08:30AM
Aug-03-23 08:00AM
Mar-21-23 04:04PM
Mar-20-23 07:31PM
Mar-15-23 09:17AM
Feb-16-23 07:30AM
Feb-09-23 11:31AM
Jan-25-23 07:30AM
07:22AM
Loading…
Dec-10-22 07:22AM
Nov-10-22 06:00AM
Nov-01-22 08:30AM
Oct-27-22 07:01AM
06:28AM
Oct-24-22 07:01AM
Oct-11-22 04:30PM
Oct-06-22 07:30AM
Sep-29-22 11:40AM
09:40AM
Sep-20-22 04:03PM
Aug-02-22 05:30PM
Jul-29-22 02:00PM
Jul-28-22 10:03AM
07:09AM
06:30AM
Loading…
Jul-26-22 06:30AM
Jul-18-22 09:40AM
Jul-14-22 11:40AM
Jul-06-22 05:38PM
Jun-30-22 09:40AM
Jun-28-22 11:40AM
Jun-27-22 06:30AM
Jun-07-22 02:00PM
(American City Business Journals)
Jun-06-22 03:57PM
(American City Business Journals)
May-31-22 01:07PM
May-30-22 07:02PM
06:50PM
05:30PM
May-05-22 07:30AM
Apr-29-22 02:00AM
Apr-28-22 09:35AM
Apr-26-22 05:35PM
Apr-25-22 07:30AM
Apr-18-22 07:30AM
Mar-24-22 11:55AM
Mar-03-22 11:40AM
10:00AM
Mar-02-22 12:20PM
10:00AM
Feb-24-22 09:40AM
Feb-15-22 11:40AM
Feb-11-22 05:04PM
Feb-10-22 12:23PM
11:01AM
06:39AM
Feb-07-22 08:38PM
Feb-02-22 08:51PM
05:30PM
Jan-31-22 01:38PM
Jan-28-22 02:48PM
Jan-27-22 01:38PM
Jan-12-22 09:38AM
Dec-24-21 01:38PM
Dec-12-21 05:32AM
Dec-07-21 02:00PM
07:00AM
(American City Business Journals)
Nov-26-21 07:33AM
(American City Business Journals)
Nov-22-21 11:04AM
Nov-14-21 08:50AM
Nov-08-21 05:32PM
02:46PM
Nov-04-21 11:15AM
Nov-02-21 03:23AM
Oct-29-21 06:01AM
Oct-28-21 09:00AM
07:29AM
07:23AM
Oct-26-21 09:48AM
Oct-07-21 02:02PM
11:17AM
09:56AM
Oct-05-21 07:30AM
Sep-07-21 07:30AM
Aug-12-21 12:00PM
Aug-02-21 07:30AM
Jul-30-21 09:02AM
Jul-29-21 02:59PM
01:38PM
10:59AM
06:37AM
Jul-20-21 11:50AM
11:40AM
Jul-19-21 07:56PM
Jul-05-21 04:41PM
Jul-01-21 06:03AM
CEMEX SAB de CV operates as a global construction materials company. It offers cement, ready-mixconcrete, aggregates, and urbanization solutions. The firm operates through the following geographical segments: Mexico, United States, Europe, Middle East, Africa and Asia (EMEAA) and South, Central America and the Caribbean (SCA&C). The company was founded by Lorenzo Zambrano Gutierrez in 1906 and is headquartered in San Pedro Garza Garcia, Mexico.
Index RUT
P/E -
EPS (ttm) -3.94
Insider Own 36.39%
Shs Outstand 61.47M
Perf Week -7.70%
Market Cap 1.94B
Forward P/E -
EPS next Y -3.26
Insider Trans -10.11%
Shs Float 51.59M
Perf Month -14.51%
Income -235.94M
PEG -
EPS next Q -0.79
Inst Own 57.66%
Short Float 15.66%
Perf Quarter 52.75%
Sales 0.00M
P/S -
EPS this Y 16.30%
Inst Trans -3.20%
Short Ratio 5.72
Perf Half Y 222.43%
Book/sh 1.49
P/B 16.07
EPS next Y 1.48%
ROA -100.10%
Short Interest 8.08M
Perf Year 126.81%
Cash/sh 1.52
P/C 15.72
EPS next 5Y -
ROE -137.31%
52W Range 6.40 - 30.27
Perf YTD 79.40%
Dividend Est. -
P/FCF -
EPS past 5Y -106.26%
ROI -206.99%
52W High -21.17%
Beta 1.03
Dividend TTM -
Quick Ratio 2.53
Sales past 5Y 0.00%
Gross Margin -
52W Low 272.81%
ATR (14) 1.62
Dividend Ex-Date -
Current Ratio 2.53
EPS Y/Y TTM -21.58%
Oper. Margin 0.00%
RSI (14) 39.58
Volatility 5.26% 6.49%
Employees 141
Debt/Eq 0.30
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 35.25
Option/Short Yes / Yes
LT Debt/Eq 0.25
EPS Q/Q -46.68%
Payout -
Rel Volume 0.69
Prev Close 23.65
Sales Surprise -
EPS Surprise -18.90%
Sales Q/Q -
Earnings Mar 05 BMO
Avg Volume 1.41M
Price 23.86
SMA20 -11.20%
SMA50 -7.70%
SMA200 57.36%
Trades
Volume 973,255
Change 0.89%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-20-24 Initiated
H.C. Wainwright
Buy
$36
Feb-27-23 Upgrade
Raymond James
Outperform → Strong Buy
$16 → $27
Feb-15-23 Initiated
Oppenheimer
Outperform
$34
Jan-26-23 Initiated
Guggenheim
Buy
$33
Jul-20-22 Initiated
Chardan Capital Markets
Buy
$17
Jul-12-22 Initiated
Raymond James
Outperform
$15
Oct-12-20 Initiated
Stifel
Buy
$29
Oct-12-20 Initiated
Piper Sandler
Overweight
$34
Oct-12-20 Initiated
JP Morgan
Overweight
$27
Oct-12-20 Initiated
Jefferies
Buy
$47
Mar-27-24 04:05PM
08:30AM
Mar-25-24 12:28PM
(Associated Press Finance) -7.72%
07:30AM
Mar-13-24 07:30AM
01:19PM
Loading…
Mar-07-24 01:19PM
Mar-05-24 10:53AM
07:30AM
Mar-02-24 12:00AM
Feb-29-24 03:02AM
Feb-14-24 04:15PM
Feb-01-24 07:30AM
Jan-26-24 11:01PM
Jan-22-24 10:14PM
Jan-12-24 01:12PM
04:05PM
Loading…
Jan-11-24 04:05PM
Jan-05-24 09:02AM
07:30AM
Jan-04-24 10:46PM
04:37PM
12:39PM
Jan-03-24 04:25PM
02:46PM
(The Wall Street Journal)
02:01PM
(The Wall Street Journal)
08:19AM
06:30AM
Jan-02-24 04:05PM
Nov-13-23 06:59PM
Nov-07-23 07:30AM
Oct-31-23 05:36AM
01:11AM
Loading…
01:11AM
Oct-30-23 07:30AM
Sep-28-23 07:30AM
Sep-20-23 04:05PM
Sep-15-23 01:52PM
Sep-14-23 01:22PM
Sep-05-23 07:30AM
Aug-28-23 10:22AM
Aug-03-23 07:30AM
Jun-16-23 08:46AM
Jun-01-23 07:30AM
May-25-23 07:30AM
May-17-23 11:25AM
07:30AM
May-11-23 07:30AM
May-03-23 07:35AM
May-02-23 04:46PM
Mar-23-23 07:30AM
Mar-20-23 07:30AM
Mar-07-23 07:30AM
Mar-02-23 07:30AM
Mar-01-23 09:00AM
(Yahoo Finance Video) +5.82%
Feb-27-23 04:40PM
Feb-05-23 05:03AM
Jan-19-23 08:23AM
Jan-18-23 08:49AM
Jan-10-23 12:00PM
Jan-03-23 07:30AM
Dec-16-22 09:55AM
Dec-09-22 09:55AM
Dec-08-22 08:10AM
Nov-30-22 09:55AM
Nov-03-22 07:30AM
Nov-02-22 07:30AM
Oct-31-22 07:30AM
Oct-12-22 06:45AM
(American City Business Journals)
Oct-11-22 04:10PM
Sep-27-22 07:30AM
Sep-12-22 07:00AM
Sep-06-22 04:30PM
07:01AM
07:00AM
Aug-29-22 07:30AM
Aug-10-22 07:30AM
Aug-04-22 07:30AM
Jul-18-22 10:00AM
Jul-12-22 02:54PM
07:30AM
Jul-05-22 07:30AM
Jul-01-22 06:58AM
Jun-03-22 07:30AM
May-16-22 07:30AM
May-02-22 04:05PM
Mar-17-22 08:45AM
Mar-10-22 07:30AM
Mar-03-22 07:30AM
Feb-02-22 01:38PM
Jan-22-22 08:06AM
Jan-18-22 04:18PM
08:00AM
Jan-05-22 07:30AM
Dec-03-21 03:30PM
Dec-02-21 08:30AM
Nov-04-21 07:30AM
Oct-26-21 10:41AM
Oct-13-21 07:45AM
Oct-01-21 10:21AM
07:30AM
Sep-28-21 07:30AM
Sep-27-21 07:30AM
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Farwell Wildon Chief Medical Officer Mar 12 '24 Sale 25.58 1,030 26,347 150,560 Mar 12 09:58 PM Brumm Joshua T CEO & President Mar 11 '24 Option Exercise 5.54 50,000 277,000 604,385 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 11 '24 Option Exercise 5.54 17,825 98,750 159,009 Mar 13 06:04 AM Brumm Joshua T CEO & President Mar 11 '24 Sale 25.67 66,387 1,704,142 537,998 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 11 '24 Sale 25.50 19,601 499,842 139,408 Mar 13 06:04 AM Scalzo Richard William SVP, Head of Finance & Admin. Mar 11 '24 Sale 25.28 2,672 67,542 119,283 Mar 12 09:57 PM HIGH SUSANNA GATTI Chief Operating Officer Mar 11 '24 Sale 25.70 2,292 58,904 156,800 Mar 13 06:04 AM Beskrovnaya Oxana Chief Scientific Officer Mar 11 '24 Sale 25.70 2,081 53,482 152,352 Mar 12 09:42 PM Farwell Wildon Chief Medical Officer Mar 11 '24 Sale 25.70 1,585 40,734 151,590 Mar 12 09:58 PM Brumm Joshua T CEO & President Mar 08 '24 Option Exercise 5.54 363,343 2,012,920 917,728 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 08 '24 Option Exercise 5.54 90,000 498,600 231,184 Mar 13 06:04 AM Scalzo Richard William SVP, Head of Finance & Admin. Mar 08 '24 Option Exercise 5.54 86,252 477,836 208,207 Mar 12 09:57 PM Brumm Joshua T CEO & President Mar 08 '24 Sale 25.93 363,343 9,421,634 554,385 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 08 '24 Sale 26.24 90,000 2,361,531 141,184 Mar 13 06:04 AM Scalzo Richard William SVP, Head of Finance & Admin. Mar 08 '24 Sale 26.22 86,252 2,261,465 121,955 Mar 12 09:57 PM HIGH SUSANNA GATTI Chief Operating Officer Mar 08 '24 Sale 26.67 27,199 725,344 159,092 Mar 13 06:04 AM Farwell Wildon Chief Medical Officer Mar 07 '24 Sale 25.86 9,921 256,585 153,175 Mar 11 09:52 PM Brumm Joshua T CEO & President Mar 07 '24 Sale 25.85 9,086 234,873 554,385 Mar 11 09:57 PM McNeill Jonathan Chief Business Officer Mar 07 '24 Sale 25.85 2,434 62,919 141,184 Mar 11 09:50 PM Beskrovnaya Oxana Chief Scientific Officer Mar 07 '24 Sale 25.85 2,373 61,342 154,433 Mar 11 09:56 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 07 '24 Sale 25.85 2,273 58,757 121,955 Mar 11 09:45 PM HIGH SUSANNA GATTI Chief Operating Officer Mar 07 '24 Sale 25.85 1,591 41,127 186,291 Mar 11 09:56 PM Brumm Joshua T CEO & President Mar 01 '24 Option Exercise 5.54 94,480 523,419 657,951 Mar 01 09:38 PM McNeill Jonathan Chief Business Officer Mar 01 '24 Option Exercise 0.73 24,260 17,710 167,878 Mar 01 09:37 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 01 '24 Option Exercise 1.03 9,311 9,590 133,539 Mar 01 09:37 PM Brumm Joshua T CEO & President Mar 01 '24 Sale 29.04 94,480 2,743,718 563,471 Mar 01 09:38 PM Rhodes Jason P Director Mar 01 '24 Sale 30.05 46,534 1,398,347 847,388 Mar 05 05:08 PM Atlas Venture Opportunity Fund 10% Owner Mar 01 '24 Sale 30.05 29,435 884,522 1,458,691 Mar 05 05:07 PM McNeill Jonathan Chief Business Officer Mar 01 '24 Sale 28.63 24,260 694,495 143,618 Mar 01 09:37 PM Atlas Venture Opportunity Fund 10% Owner Mar 01 '24 Sale 30.05 17,099 513,825 847,388 Mar 05 05:07 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 01 '24 Sale 28.25 9,311 262,999 124,228 Mar 01 09:37 PM Brumm Joshua T CEO & President Feb 29 '24 Option Exercise 5.54 5,520 30,581 568,991 Mar 01 09:38 PM Scalzo Richard William SVP, Head of Finance & Admin. Feb 29 '24 Option Exercise 1.03 3,429 3,532 127,657 Mar 01 09:37 PM McNeill Jonathan Chief Business Officer Feb 29 '24 Option Exercise 0.73 4,268 3,116 147,886 Mar 01 09:37 PM Brumm Joshua T CEO & President Feb 29 '24 Sale 27.50 5,520 151,800 563,471 Mar 01 09:38 PM McNeill Jonathan Chief Business Officer Feb 29 '24 Sale 27.50 4,268 117,370 143,618 Mar 01 09:37 PM Scalzo Richard William SVP, Head of Finance & Admin. Feb 29 '24 Sale 27.50 3,429 94,298 124,228 Mar 01 09:37 PM Rhodes Jason P Director Feb 28 '24 Sale 24.84 190,920 4,741,804 864,487 Feb 28 07:15 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 28 '24 Sale 24.84 154,674 3,841,576 5,698,091 Feb 28 07:13 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 28 '24 Sale 24.84 36,246 900,228 864,487 Feb 28 07:13 PM Rhodes Jason P Director Feb 27 '24 Sale 24.41 368,699 8,998,426 877,806 Feb 28 07:15 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 27 '24 Sale 24.41 298,702 7,290,088 5,852,765 Feb 28 07:13 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 27 '24 Sale 24.41 69,997 1,708,338 877,806 Feb 28 07:13 PM Rhodes Jason P Director Feb 26 '24 Sale 23.72 248,219 5,886,673 903,527 Feb 28 07:15 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 26 '24 Sale 23.72 201,095 4,769,096 6,151,467 Feb 28 07:13 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 26 '24 Sale 23.72 47,124 1,117,577 903,527 Feb 28 07:13 PM Rhodes Jason P Director Feb 23 '24 Sale 22.70 196,928 4,470,266 920,843 Feb 23 06:59 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 23 '24 Sale 22.70 159,542 3,621,603 6,352,562 Feb 23 06:58 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 23 '24 Sale 22.70 37,386 848,662 920,843 Feb 23 06:58 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 22 '24 Sale 22.66 119,360 2,704,698 6,512,104 Feb 23 06:58 PM Rhodes Jason P Director Feb 22 '24 Sale 22.66 119,360 2,704,698 6,512,104 Feb 23 06:59 PM Rhodes Jason P Director Feb 21 '24 Sale 22.57 184,501 4,164,817 6,631,464 Feb 23 06:59 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 21 '24 Sale 22.57 184,501 4,164,817 6,631,464 Feb 23 06:58 PM Rhodes Jason P Director Feb 20 '24 Sale 22.72 169,539 3,852,653 6,815,965 Feb 20 06:36 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 20 '24 Sale 22.72 169,539 3,852,653 6,815,965 Feb 20 06:35 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 16 '24 Sale 23.14 162,707 3,765,040 6,985,504 Feb 20 06:35 PM Rhodes Jason P Director Feb 16 '24 Sale 23.14 162,707 3,765,040 6,985,504 Feb 20 06:36 PM Rhodes Jason P Director Feb 15 '24 Sale 23.89 177,906 4,249,600 7,148,211 Feb 20 06:36 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 15 '24 Sale 23.89 177,906 4,249,600 7,148,211 Feb 20 06:35 PM Farwell Wildon Chief Medical Officer Feb 12 '24 Sale 25.07 5,493 137,710 163,503 Feb 14 04:27 PM McNeill Jonathan Chief Business Officer Jan 26 '24 Option Exercise 0.73 20,000 14,600 163,618 Jan 26 07:48 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 26 '24 Option Exercise 1.03 13,000 13,390 137,228 Jan 26 07:47 PM McNeill Jonathan Chief Business Officer Jan 26 '24 Sale 24.53 20,000 490,510 143,618 Jan 26 07:48 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 26 '24 Sale 24.34 13,000 316,420 124,228 Jan 26 07:47 PM Farwell Wildon Chief Medical Officer Jan 26 '24 Sale 25.00 100 2,500 168,996 Jan 26 07:49 PM Kersten Dirk Director Jan 09 '24 Buy 17.50 1,714,285 29,999,988 6,416,793 Jan 11 04:31 PM Brumm Joshua T CEO & President Jan 04 '24 Option Exercise 5.16 218,536 1,127,092 803,507 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 04 '24 Option Exercise 1.03 22,674 23,354 199,259 Jan 04 09:48 PM McNeill Jonathan Chief Business Officer Jan 04 '24 Option Exercise 0.73 2,009 1,467 145,627 Jan 04 09:47 PM Brumm Joshua T CEO & President Jan 04 '24 Sale 18.51 218,536 4,045,958 584,971 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 04 '24 Sale 18.13 42,453 769,673 156,806 Jan 04 09:48 PM McNeill Jonathan Chief Business Officer Jan 04 '24 Sale 18.04 2,009 36,242 143,618 Jan 04 09:47 PM Brumm Joshua T CEO & President Jan 03 '24 Option Exercise 1.03 51,183 52,718 636,154 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 03 '24 Option Exercise 1.03 45,326 46,686 221,911 Jan 04 09:48 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 03 '24 Option Exercise 1.03 13,000 13,390 137,228 Jan 04 09:46 PM McNeill Jonathan Chief Business Officer Jan 03 '24 Option Exercise 0.73 17,991 13,133 161,609 Jan 04 09:47 PM Brumm Joshua T CEO & President Jan 03 '24 Sale 19.28 51,183 986,957 584,971 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 03 '24 Sale 18.98 45,326 860,313 176,585 Jan 04 09:48 PM McNeill Jonathan Chief Business Officer Jan 03 '24 Sale 18.74 17,991 337,062 143,618 Jan 04 09:47 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 03 '24 Sale 18.81 13,000 244,530 124,228 Jan 04 09:46 PM McNeill Jonathan Chief Business Officer Jan 02 '24 Sale 13.10 11,900 155,890 143,618 Jan 04 09:47 PM Scalzo Richard William See Remarks Dec 14 '23 Sale 12.02 2,376 28,560 124,228 Dec 14 04:59 PM Farwell Wildon Chief Medical Officer Dec 12 '23 Sale 10.55 978 10,318 169,096 Dec 12 05:33 PM Brumm Joshua T See Remarks Dec 11 '23 Sale 10.72 7,585 81,311 584,971 Dec 12 05:33 PM Farwell Wildon Chief Medical Officer Dec 11 '23 Sale 10.72 1,688 18,095 170,074 Dec 12 05:33 PM HIGH SUSANNA GATTI Chief Operating Officer Dec 11 '23 Sale 10.72 1,616 17,324 187,882 Dec 12 05:34 PM Beskrovnaya Oxana Chief Scientific Officer Dec 11 '23 Sale 10.72 1,467 15,726 176,585 Dec 12 05:32 PM Scalzo Richard William See Remarks Dec 11 '23 Sale 10.72 1,380 14,794 126,604 Dec 12 05:35 PM McNeill Jonathan Chief Business Officer Dec 11 '23 Sale 10.72 1,245 13,346 155,518 Dec 12 05:34 PM Scalzo Richard William See Remarks Dec 06 '23 Sale 12.01 1,872 22,483 127,984 Dec 06 06:13 PM Scalzo Richard William See Remarks Dec 04 '23 Sale 12.01 681 8,179 129,856 Dec 06 06:13 PM HIGH SUSANNA GATTI Chief Operating Officer Nov 02 '23 Sale 7.40 9,939 73,549 94,605 Nov 02 05:16 PM Brumm Joshua T See Remarks Sep 18 '23 Sale 9.41 12,032 113,221 233,679 Sep 20 04:47 PM HIGH SUSANNA GATTI Chief Operating Officer Sep 18 '23 Sale 9.41 2,672 25,144 104,544 Sep 20 04:48 PM Beskrovnaya Oxana Chief Scientific Officer Sep 18 '23 Sale 9.41 1,436 13,513 84,334 Sep 20 04:47 PM Scalzo Richard William See Remarks Sep 18 '23 Sale 9.41 1,290 12,139 40,795 Sep 20 04:49 PM McNeill Jonathan Chief Business Officer Sep 18 '23 Sale 9.41 1,261 11,866 60,605 Sep 20 04:49 PM Brumm Joshua T See Remarks Sep 12 '23 Sale 10.41 7,672 79,866 245,711 Sep 13 07:50 PM Farwell Wildon Chief Medical Officer Sep 12 '23 Sale 10.41 1,707 17,770 89,250 Sep 13 07:56 PM HIGH SUSANNA GATTI Chief Operating Officer Sep 12 '23 Sale 10.41 1,635 17,020 107,216 Sep 13 07:51 PM
Index RUT
P/E 13.45
EPS (ttm) 0.44
Insider Own 2.26%
Shs Outstand 471.50M
Perf Week -3.55%
Market Cap 2.82B
Forward P/E 6.69
EPS next Y 0.89
Insider Trans -15.06%
Shs Float 460.82M
Perf Month -1.16%
Income 213.52M
PEG 0.57
EPS next Q 0.17
Inst Own 95.99%
Short Float 8.38%
Perf Quarter -5.97%
Sales 1.72B
P/S 1.64
EPS this Y -2.28%
Inst Trans 0.35%
Short Ratio 4.73
Perf Half Y -21.93%
Book/sh 2.24
P/B 2.67
EPS next Y 15.70%
ROA 4.49%
Short Interest 38.62M
Perf Year -17.40%
Cash/sh 0.20
P/C 29.57
EPS next 5Y 23.80%
ROE 23.46%
52W Range 5.23 - 8.28
Perf YTD -10.88%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI 6.21%
52W High -27.78%
Beta 2.35
Dividend TTM -
Quick Ratio 0.49
Sales past 5Y 26.57%
Gross Margin 48.96%
52W Low 14.34%
ATR (14) 0.25
Dividend Ex-Date Mar 04, 2020
Current Ratio 0.76
EPS Y/Y TTM -6.52%
Oper. Margin 42.74%
RSI (14) 49.72
Volatility 3.50% 4.33%
Employees 243
Debt/Eq 2.33
Sales Y/Y TTM -23.90%
Profit Margin 12.42%
Recom 1.36
Target Price 8.40
Option/Short Yes / Yes
LT Debt/Eq 2.33
EPS Q/Q 117.91%
Payout 0.00%
Rel Volume 0.44
Prev Close 6.06
Sales Surprise 7.51%
EPS Surprise 29.17%
Sales Q/Q 0.74%
Earnings May 07 BMO
Avg Volume 8.17M
Price 5.98
SMA20 -0.15%
SMA50 2.00%
SMA200 -10.25%
Trades
Volume 3,585,896
Change -1.32%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Initiated
Stifel
Buy
$10
Oct-17-23 Downgrade
Bernstein
Outperform → Mkt Perform
$12 → $9
Sep-27-23 Upgrade
BofA Securities
Neutral → Buy
$8.70 → $10
Jul-20-23 Initiated
Redburn
Buy
$9
Mar-10-23 Initiated
Peel Hunt
Add
$8.94
Feb-28-23 Downgrade
BofA Securities
Buy → Neutral
$10 → $9.60
Feb-09-23 Initiated
The Benchmark Company
Buy
$10
Aug-25-22 Upgrade
Berenberg
Hold → Buy
$8.30 → $8.50
Jun-13-22 Downgrade
Berenberg
Buy → Hold
Nov-11-21 Upgrade
Barclays
Equal Weight → Overweight
$3.95
Oct-15-21 Upgrade
Berenberg
Hold → Buy
Jun-21-21 Upgrade
Bernstein
Mkt Perform → Outperform
Jun-08-21 Upgrade
Johnson Rice
Accumulate → Buy
$4.50 → $6.25
May-17-21 Upgrade
BofA Securities
Neutral → Buy
$3.50 → $3.70
Mar-09-21 Upgrade
Johnson Rice
Hold → Accumulate
Feb-24-21 Downgrade
Berenberg
Buy → Hold
Feb-23-21 Upgrade
Goldman
Neutral → Buy
$2.40 → $4.50
May-14-20 Downgrade
Goldman
Buy → Neutral
May-13-20 Upgrade
RBC Capital Mkts
Underperform → Sector Perform
Apr-21-20 Downgrade
Investec
Buy → Hold
Show Previous Ratings
Apr-11-24 02:00AM
Mar-28-24 01:59PM
09:31AM
Mar-26-24 04:14PM
Mar-08-24 09:43AM
02:00AM
Loading…
Mar-06-24 02:00AM
Mar-04-24 04:08PM
Feb-28-24 10:53AM
08:38AM
Feb-27-24 01:29AM
(Thomson Reuters StreetEvents)
Feb-26-24 06:52AM
05:07AM
(Associated Press Finance)
02:00AM
Feb-08-24 02:23AM
Feb-06-24 06:50AM
07:55AM
Loading…
Feb-05-24 07:55AM
Feb-01-24 07:50PM
Jan-31-24 05:11AM
Jan-18-24 02:00AM
Jan-15-24 01:00PM
Nov-13-23 07:15PM
Nov-09-23 10:00AM
Nov-07-23 11:11AM
01:12AM
(Thomson Reuters StreetEvents)
Nov-06-23 10:06AM
08:17AM
05:03AM
(Associated Press Finance)
02:00AM
02:00AM
Nov-02-23 05:46AM
02:39AM
Loading…
Oct-17-23 02:39AM
Oct-12-23 08:24AM
Oct-11-23 02:00AM
Oct-06-23 02:00AM
Oct-04-23 12:36PM
Sep-28-23 03:10AM
Sep-26-23 07:34PM
Sep-16-23 08:34AM
Sep-13-23 10:53AM
Aug-09-23 09:51AM
Aug-08-23 03:26AM
(Thomson Reuters StreetEvents)
Aug-07-23 05:02AM
02:00AM
Jul-22-23 08:24AM
Jul-14-23 02:00AM
Jul-06-23 02:00AM
Jun-28-23 02:06PM
Jun-12-23 08:53AM
Jun-08-23 07:53AM
May-09-23 05:03AM
02:00AM
Apr-26-23 02:00AM
Apr-19-23 02:00AM
Apr-11-23 01:30PM
Mar-17-23 05:54PM
Mar-12-23 11:55PM
Mar-04-23 09:08AM
Mar-01-23 10:10AM
Feb-28-23 03:52AM
(Thomson Reuters StreetEvents) -7.95%
Feb-27-23 02:02AM
Feb-02-23 06:29AM
Jan-27-23 02:00AM
Jan-23-23 06:55AM
Jan-04-23 06:00PM
Dec-31-22 09:43AM
Dec-27-22 11:39AM
Dec-20-22 09:24AM
Dec-05-22 09:40AM
Nov-17-22 09:40AM
Nov-10-22 07:26AM
Nov-07-22 09:55AM
02:00AM
Nov-02-22 12:20PM
Oct-25-22 01:57PM
08:32AM
06:12AM
Oct-20-22 01:23PM
09:55AM
09:30AM
Oct-18-22 01:08PM
02:00AM
Sep-27-22 02:00AM
Sep-24-22 05:30AM
Sep-23-22 02:25PM
Sep-16-22 05:00PM
Sep-05-22 09:35AM
Aug-30-22 11:15AM
Aug-26-22 07:09AM
Aug-19-22 03:35PM
09:30AM
Aug-08-22 05:00PM
09:35AM
02:00AM
Aug-01-22 09:55AM
Jul-26-22 06:00PM
Jul-24-22 09:24AM
Jul-21-22 02:00AM
Jul-20-22 06:15PM
Jul-14-22 06:17PM
Jul-08-22 06:15PM
Kosmos Energy Ltd. engages in the exploration, development, and production of oil and gas. The firm's assets include production offshore Ghana, Equatorial Guinea and the U.S. Gulf of Mexico, as well as a gas development offshore Mauritania and Senegal. It also maintains a sustainable exploration program balanced between proven basin infrastructure-led exploration, emerging basins, and frontier basins. The company was founded by Brian F. Maxted on April 23, 2003 and is headquartered in Dallas, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
INGLIS ANDREW G Chairman and CEO Feb 06 '24 Sale 5.66 177,430 1,003,917 3,376,816 Feb 07 04:19 PM Ball Christopher James SVP, Chief Commercial Officer Feb 06 '24 Sale 5.66 121,915 689,807 1,409,244 Feb 07 04:16 PM Shah Nealesh D. SVP and CFO Feb 06 '24 Sale 5.66 90,454 511,798 1,230,830 Feb 07 04:20 PM Doughty Jason SVP and General Counsel Feb 06 '24 Sale 5.66 71,227 403,009 1,244,324 Feb 07 04:17 PM Glass Ronald W. VP & Chief Accounting Officer Feb 06 '24 Sale 5.66 18,693 105,767 234,773 Feb 07 04:18 PM INGLIS ANDREW G Chairman and CEO Feb 05 '24 Sale 5.49 182,948 1,003,927 3,554,246 Feb 07 04:19 PM Ball Christopher James SVP, Chief Commercial Officer Feb 05 '24 Sale 5.49 125,707 689,817 1,531,159 Feb 07 04:16 PM Shah Nealesh D. SVP and CFO Feb 05 '24 Sale 5.49 93,267 511,803 1,321,284 Feb 07 04:20 PM Doughty Jason SVP and General Counsel Feb 05 '24 Sale 5.49 73,442 403,013 1,315,551 Feb 07 04:17 PM Glass Ronald W. VP & Chief Accounting Officer Feb 05 '24 Sale 5.49 19,274 105,766 253,466 Feb 07 04:18 PM INGLIS ANDREW G Chairman and CEO Feb 02 '24 Sale 5.84 171,941 1,003,929 3,737,194 Feb 02 05:53 PM Ball Christopher James SVP, Chief Commercial Officer Feb 02 '24 Sale 5.84 118,144 689,819 1,656,866 Feb 02 05:46 PM Shah Nealesh D. SVP and CFO Feb 02 '24 Sale 5.84 87,655 511,800 1,414,551 Feb 02 05:55 PM Doughty Jason SVP and General Counsel Feb 02 '24 Sale 5.84 69,025 403,023 1,388,993 Feb 02 05:49 PM Glass Ronald W. VP & Chief Accounting Officer Feb 02 '24 Sale 5.84 18,115 105,770 272,740 Feb 02 05:51 PM INGLIS ANDREW G Chairman and CEO Feb 01 '24 Sale 6.03 166,524 1,003,923 3,909,135 Feb 02 05:53 PM Ball Christopher James SVP, Chief Commercial Officer Feb 01 '24 Sale 6.03 114,423 689,822 1,775,010 Feb 02 05:46 PM Shah Nealesh D. SVP and CFO Feb 01 '24 Sale 6.03 84,672 510,462 1,502,206 Feb 02 05:55 PM Doughty Jason SVP and General Counsel Feb 01 '24 Sale 6.03 66,616 401,608 1,458,018 Feb 02 05:49 PM Glass Ronald W. VP & Chief Accounting Officer Feb 01 '24 Sale 6.03 17,525 105,653 290,855 Feb 02 05:51 PM GOODWIN DEANNA L Director Jun 09 '23 Sale 6.69 112,000 749,280 99,532 Jun 12 04:08 PM Franklin Roy A. Director Jun 09 '23 Sale 6.80 8,000 54,400 68,870 Jun 12 04:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite